Novo Nordisk receives FDA approval for its obesity drug

The US regulatory body has approved the company’s Saxenda for the treatment of obesity


The company wil launch the drug in the american market in the first half of 2015

Novo Nordisk has announced that the US Food and Drug Administration (US FDA) has approved the New Drug Application (NDA) for Saxenda (liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity.

Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI =>30 kg/m2) or who are overweight (BMI =>27 kg/m2) with at least one weight-related comorbidity such as type 2 diabetes and cardiovascular disease.

"Many people with obesity suffer from comorbidities. Saxenda has the potential to help some of these people achieve and maintain a clinically significant weight loss and improve their weight-related comorbidities," said Mr Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

Novo Nordisk expects to launch the drug in the US in the first half of 2015.



Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email